Understand the source comparison
Peptides for Brain Fog: Mechanism Comparison
Cerebrolysin BDNF/NGF receptor agonism, reduces amyloid-beta aggregation Partial. Requires IV/IM administration for optimal delivery Phase III trials in vascular dementia (CNS Drugs, 2015) Most clinically validated nootropic peptide. Direct neurotrophic signal
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF receptor agonism, reduces amyloid-beta aggregation
- Partial. Requires IV/IM administration for optimal delivery
- Phase III trials in vascular dementia (CNS Drugs, 2015)
- Most clinically validated nootropic peptide. Direct neurotrophic signaling with consistent cognitive improvements in controlled trials
- P21
- CNTF receptor activation, promotes hippocampal neurogenesis
- High. Crosses BBB efficiently as a small synthetic peptide
- Animal models only (University of Washington, 2019)
- Strong preclinical evidence but lacks human trial data. Mechanism is biologically sound but clinical translation unconfirmed
- Dihexa
- HGF receptor agonism, promotes synaptogenesis
- Moderate. Oral bioavailability documented in rodent models
- Preclinical only (Arizona State, 2017)
- Extremely potent in animal models (7 orders > BDNF) but human safety and efficacy data absent. High theoretical potential, unproven clinically
- MK 677
- Growth hormone secretagogue, increases IGF-1 and mitochondrial biogenesis
- Low direct BBB penetration. Acts peripherally on GH/IGF-1 axis
- Phase II trials for sarcopenia, indirect cognitive benefits noted
- Indirect cognitive support through metabolic pathways. Not a nootropic in the traditional sense but documented improvements in sleep quality and neuronal energy metabolism